LRG1 predicts kidney disease progression in type 2 diabetes patients

The study summary is as follows:

• There were 1,837 participants with type 2 diabetes and eGFR >30 mL/min/1.73 m2.
• Urine LRG1 measurement at baseline (cohort enrolment).
• Survival analysis to study the association of urine LRG1 with the risk of ESKD.
• The duration of the mean follow-up was 8.6 years.
• 134 ESKD events were identified (sustained eGFR < 15 ml/min/1.73 m2, dialysis or renal death.
• The study participants with urine LRG1 in the highest tertile had a significantly higher risk for ESKD progression.
• One SD increment was associated with a 1.53-fold adjusted risk of ESKD.
• Urine LRG1 was associated with a rapid decline in kidney function (eGFR decline 5ml/min/1.73 m2 per year or greater) and risk for progression to macroalbuminuria.

To conclude, Urine LRG1 predicts the risk of ESKD progression independently of clinical risk factors in T2D patients. This is a valuable marker to indicate the progression to ESKD.

The participants in the highest tertile of urine LRG1 levels had a significantly higher risk for incident ESKD.

Citation

Jian-Jun Liu et al. Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care 2022; dc221611. https://doi.org/10.2337/dc22-1611